Experimental combo aims to tackle returning head and neck cancer
NCT ID NCT07545967
First seen Apr 25, 2026 · Last updated Jun 23, 2026 · Updated 11 times
Summary
This early-stage trial is testing whether giving a drug called chidamide along with a second round of radiation is safe for people whose head and neck cancer has returned after previous radiation. Only 6 participants will be enrolled to find the best dose and check for side effects. The goal is to see if this combination can help control the cancer without causing too many severe problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Chidamide (a type of drug called a histone deacetylase inhibitor, taken orally)
What this could lead to
If successful, this could point toward a new treatment option for patients whose head and neck cancer has come back after radiation therapy.
What could go wrong
This is a very early, small Phase 1 trial with only 6 participants, so results may not apply broadly. The combination of re-irradiation and chidamide may cause serious side effects, and it is not yet known if it will effectively control the cancer.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.